FANG vaccine from Gradalis shows teeth in ovarian cancer
This article was originally published in Scrip
Executive Summary
Gradalis asked the US FDA to consider a breakthrough therapy designation for its personalized cancer vaccine known as FANG based on interim Phase II data that show a 140% improvement in recurrence rates versus the standard of care for women with advanced ovarian cancer.